CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IO

CheckMate 816: what does the data tell us?Подробнее

Surgical outcomes from the Phase III CheckMate 816 trialПодробнее

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...Подробнее

Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022Подробнее

Perioperative therapies in NSCLCПодробнее

Event-free survival results from CheckMate 816Подробнее

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLCПодробнее

Surgical outcomes from CheckMate 816: NIVO plus chemo vs chemo alone as neoadjuvant treatment fo...Подробнее

The CheckMate 816 Trial: The Success of Adjuvant NSCLC Therapies - Lung Cancer OncTalk 2022Подробнее

Future directions for neoadjuvant immunotherapy in lung cancerПодробнее

Nodal recurrence following axillary downstaging with neoadjuvant chemotherpay + omission of ALNDПодробнее

Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLCПодробнее

Watch Drs Broderick & Wakelee discuss the latest in NSCLC: https://bit.ly/2021-NSCLCПодробнее

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023Подробнее

Immunotherapy as combination and neoadjuvant therapies in NSCLCПодробнее

Can we improve the surgical outcomes in resectable lung cancer by adding preoperative immunotherapy?Подробнее

Dr. Patrick Forde Discusses 3-Year CheckMate 816 NSCLC Results at ASCO 2023Подробнее

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Подробнее